With the clock ticking on Sandoz’s place within its operations, Novartis has ratcheted up its generic and biosimilar division’s full-year revenue guidance for 2023, after Sandoz’s sales climbed by 8% in constant currencies in the first three months of the year.
Having previously laid out a forecast for Sandoz’s top line to show low- to mid-single digit growth in CC in...







